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Resistance to parathyroid hormone in renal failure: Role of vita-
mm D metabolites. Resistance to the calcemic action of para-
thyroid extract (PTE) was shown in thyroparathyroidectomized
rats after 5 hr of renal failure that was induced by either bi-
lateral nephrectomy (NPX) or ureter ligation (UL). Studies
were carried out to investigate the relationship of parathyroid
resistance to the vitamin D status of the animal. Concentrations
of I ,25-dihydroxycholecalciferol (I ,25(OH)2D3) and 24,25-dihy-
droxycholecalciferol (24,25(OH)2D3) were similar in pooled sera
samples from rats either UL or sham-operated and treated with
PTE. Pretreatment with oral 25-hydroxycholecalciferol or with
a combination of i.v. 24,25(OH)2D3 and I ,25(OH)2D3 prior to UL
failed to alter the resistance. Resistance was also present in a
group in vitamin-D-deficient rats. A similar group given I g of
vitamin D2 showed more parathyroid resistance than did the
group not given vitamin D2. In chronic renal failure of 28 day's
duration, parathyroid resistance was again demonstrated, but, in
contrast to the acute renal failure models, this was partly cor-
rected by prior l,25(OH)2D3 administration. These studies show
that parathyroid resistance is not caused by an abnormality of
vitamin D metabolism in the acute renal failure model, and we
suggest that the phenomenon is due to the accumulation of one
or more uremic factors.
Résistance a l'hormone parathyroIdienne au cours de l'insuf-
fisance rénale: Role des métabolites de Ia vitamine D. La résis-
tance a l'action hypercalcémiante de l'extrait parathyroIdien
(PTE) a été misc en evidence chez des rats thyroparathyroid-
ectomisés aprCs 5 heures d'insuffisance rCnale dCterminée soit
par néphrectomie bilatCrale (NPX) ou ligature urCtérale(UL). L'étude a porte sur Ia relation entre Ia résistance a
PTE et l'état de l'animal en cc qui concerne Ia vitamine D. Les
concentrations de I ,25-dihydroxycholécalciférot (I ,25(OH)2D3)
et de 24,25-dihydroxycholecalcifCrol (24,25(OH)2D3) sont scm-
blables dans Ic serum de rats UL ou ayant subi un simulacre
d'intervention et traités par PTE. Le traitement prealable par Ic
25-hydroxycholecalcifCrol par voie orate ou t'association de
24,25(OH)2D3 et de I ,25(OH)2D3 administrés par voie veineuse
avant La ligature urétérale n'ont pas modiflé Ia résistance. La
résistance a ete constatée aussi dans un groupe de rats carencés
en vitamine D. Un groupe semblable qui a recu I g de vitamine
D2 a eu une résistance plus importante que Ic groupe qui n'a pas
recu de vitamine D2. Dans l'insuffisance rénale chronique
évoluant depuis 28 jours, La résistance existe encore mais, a Ia
difference de l'insuffisance rénale aiguC, dIe est partiellement
corrigee par l'administration prealable de I ,25(OH)2D3. Ces ré-
sultats montrent que Ia résistance n'est pas liée a une anomalie
du métabolisme de La vitamine D dans Ic modéle utilisant
l'insuffisance rénale aigue et nous suggérons que cc phenomène
est dO a l'accumulation d'un ou pLusieurs facteurs urémiques.
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Resistance to the calcemic action of parathyroid
hormone in renal failure is now accepted as an im-
portant factor in the development of secondary hy-
perparathyroidism. It was first described by Evan-
son in 1966 [1] and has been further characterized
by Massry et al. They have demonstrated this phe-
nomenon to occur in humans with chronic renal fail-
ure before and during dialysis [2], in acute renal fail-
ure [3], and in patients with early renal failure [4].
The mechanism of this parathyroid resistance is not
understood completely although it has been sug-
gested that a deficiency of the active metabolite
of vitamin D, 1 ,25-dihydroxycholecalciferol (1,25-
(OH)2D3), which is produced in the kidney [5], is
at least partly responsible [6]. In subsequent stud-
ies [7], it has been suggested that the resistance
could also be due to uremia interfering with further
metabolism of 1 ,25(OH)2D3 and that the presence of
metabolites other than 1 ,25(OH)2D3 may be impor-
tant. To help clarify the role of vitamin D metabo-
lites in this resistance to parathyroid hormone, we
have carried out a series of studies in rats, using
acute and chronic renal failure models of 5 hour's
and 28 day's duration, respectively. In these models
the vitamin D status was altered by dietary manipu-
lation and pretreatment with a variety of vitamin D
metabolites. In addition, at the time of demonstrat-
ing the impaired calcemic response, we measured
the serum concentrations of both 1,25(OH)2D3
and 24,25-dihydroxycholecalciferol (24,25(OH)2D3).
Our results indicate that vitamin D metabolites do
not play a significant part in the parathyroid hor-
mone resistance of the acute renal failure model but
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may play a role in the resistance of the chronic renal
failure model.
Methods
All rats were maintained in an air-conditioned
room that was lighted by incandescent light from
midnight to noon and left dark the remaining 12 hr.
They were fed ad lib for at least 3 days prior to
use, a semisynthetic diet [8] containing 0.7% phos-
phate, 0.9% calcium, and 2 g of vitamin D2 per 100
g of body wt. When a calcium-free or vitamin-D-
free, or low-phosphate diet was used, the formula-
tion was otherwise unchanged. The analyzed cal-
cium content of the calcium-free diet was 0.0 1%. In
the vitamin-D-deficient and chronic renal failure
studies, male rats of the Holtzman strain were used;
otherwise, the rats were Sprague-Dawley males,
each rat weighing about 150 g.
As a source of parathyroid hormone, parathyroid
extract (PTE; Lilly Co.), 100 U/mI, was injected
s.c. in doses of 40 U/100 g for all experiments, un-
less stated otherwise. The commercial preparation
was diluted to the appropriate strength by mixing it
with a solution containing 16 g of glycerol, 2 g of
phenol, and 9 g of sodium chloride per liter; the final
pH was adjusted to 2.8 with normal hydrochloric
acid. Control rats were given an equivalent volume
of the diluent. The 25-hydroxyvitamin D (25-OH-
D3) was obtained from Roussel Laboratories, and
the 1,25(OH)2D3 and the 24,25(OH)2D3 were ob-
tained from Roche Laboratories. The former was
administered by gavage in propanediol, and the lat-
ter two were administered by an i.v. injection in
50 d of 95% ethanol. As controls, the appropriate
vehicle was administered alone.
Thyroparathyroidectomy (TPTX) was carried out
under light ether anesthesia; the thyroid and para-
thyroid glands were removed with forceps under a
dissecting microscope. This operation was per-
formed to remove endogenous parathyroid hor-
mone and calcitonin, which could have affected the
final plasma calcium concentration. In some of the
studies, detailed in the following, rats were used
that had been subjected to TPTX approximately 7
to 10 days earlier (chronic TPTX). Following
TPTX, these rats were given 0.7% calcium lactate
to drink for 2 days, 0.3% calcium lactate for 2 days,
then deionized water until the day of study. The
standard diet was continued throughout this period,
and L-thyroxine was injected s.c., 5 jsg/100 g of
body wt, three times per week. Plasma calcium con-
centration was determined from tail blood samples
2 to 3 days prior to the experiment, and any animals
with values in excess of 8.5 mgldl were discarded.
Acute urenia
Time course response to parathyroid extract
(PTE) in acute uremia. On the day of study, a cath-
eter was placed in the carotid artery of chronic
TPTX rats, which were then divided into four
groups for the following procedures: (I) bilateral ne-
phrectomy (NPX) followed by injection of PTE, 40
U/100 g; (2) NPX followed by injection of an equiv-
alent volume of diluent; (3) sham abdominal opera-
tion followed by injection of PTE, 40 U/100 g; and
(4) sham operation followed by injection of diluent.
Blood samples were obtained from each rat for de-
termining the calcium concentration immediately
prior to injection, then hourly for 10 hr, and finally
24 hr after injection. Blood losses were replaced by
sterile, heparinized, donor blood obtained from a
normal rat. The parathyroid effect at time of blood
sampling was calculated by subtracting the mean
calcium concentration of the appropriate diluent
group at the same time, from each of the plasma
calcium concentration of the PTE-treated animals.
This gave the net change in calcium concentration
for that particular PTE-treated animal.
PTE dose response in acute uremia. In this study,
all rats were TPTX immediately prior to either a bi-
lateral ureter ligation (UL) or a sham abdominal op-
eration (referred to as "acute TPTX"). At the end
of the surgical procedure, four groups from the ure-
mic and four groups from the kidney-intact classes.
each group consisting of seven rats, were injected
with P1'E, 40 p1/mI strength, in doses of 40 U/100 g,
or 20 U/tOO g, or 10 U/100 g, or a volume of diluent
equivalent to the 40 U/100 g PTE dose. In this ex-
periment and in all studies described subsequently,
the animals were killed by aortic bleeding 5 hr after
injection of PTE or diluent.
Ureteral ligation (UL) versus bilateral nephrecto-
my (NPX). The aim of this study was to determine
whether the calcemic response to PTE in uremia
produced by NPX was different from that in uremia
produced by UL. Rats were acutely TPTX; UL or a
sham operation were then performed. One-half of
each group was injected with PTE, 40 U/100 g. and
the other half was injected with an equivalent vol-
ume of diluent. Five hours after injection, blood
samples were taken from the animals for determina-
tion of calcium concentration.
Alteration in dietary phosphorus: Effect on PTE
response in acute uremia. Chronic TPTX rats were
prepared as described above. Ten to twelve days
after TPTX and 72 hr prior to the day of study, they
were divided into two weight-matched groups. One
group was allowed to remain on the regular (0.7%
phosphorus) diet, and the other group was given a
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diet similar but containing only 0.2% phosphorus.
On the day of study, the blood samples were taken
from the tail vein for determining the concentration
of calcium and phosphorus; then each group was
further subdivided into four groups (eight to nine
rats per group) according to the following proce-
dures: (1) sham abdominal operation followed by in-
jection of PTE, 40 U/100 g; (2) sham operation fol-
lowed by injection of diluent; (3) UL followed by
injection of PTE, 40 U/100 g; and (4) UL followed
by injection of diluent.
Relationship of serum vitamin D metabolite con-
centrations to PTE response in acute uremia. All 32
rats, previously on a calcium-free diet for 96 hr, un-
derwent acute TPTX. Then, they underwent either
UL or a sham abdominal operation. Half of each
subgroup was given PTE, 40 U/l00 g, and the other
half was given diluent. Five hours later, they were
bled from the aorta, an aliquot of serum from each
rat was used to measure calcium concentration, and
the remainder was pooled into four lots, one for
each group, and then stored until the D metabolites
were measured.
Pre-treatment with a pharmacologic dose of 25-
OH-D3: Effect on the calcemic response to PTE in
acute uremia. In this experiment two groups of
eight rats were given a calcium-free diet 96 hr prior
to the day of study. Forty-eight hours prior to
study, one group was given 150 jsg of 25-OH-D3 by
gavage, and the other was given the vehicle. On the
day of study, blood samples were taken from all ani-
mals for determination of calcium concentration.
Then, acute TPTX and UL were performed. At the
end of the operation, PTE, 40 U/100 g, was given.
All rats were killed 5 hr alter the injection. As
described in the previous experiment, an aliquot of
serum from each animal was taken for measurement
of the calcium concentration; the remainder was
pooled into two lots for measurement of the vitamin
D metabolite concentrations.
Vitamin D depletion and repletion with one mi-
crogram of vitamin D2: Effect on the calcemic re-
sponse to PTE in acute uremia. For this experi-
ment, 128 weanling rats were placed on the vitamin-
D-deficient diet for 5 weeks. After this period of
time, the plasma calcium concentrations were mea-
these values were found to range between 6.1
mgilOO ml and 10.4 mg/100 ml. Sixty-four of these
rats with plasma calcium concentrations greater
than 8.4 mg!100 ml and less than 10.0 mg/100 ml
were selected and then were divided into groups
matched in number, weight, and plasma calcium
concentration. One group was given I g of vita-
min D2 in oil by gavage 48 hr prior to use; the other
group was continued on the vitamin-D-deficient
diet. On the day of study, each group was sub-
divided as follows: (1) rats that had had TPTX-sham
abdominal operation and PTE injection; (2) rats that
had had TPTX-sham abdominal operation and
diluent injection; (3) rats that had had TPTX-UL
and P1'E injection; and (4) rats that had had TPTX-
UL and diluent injection. Blood samples were taken
from all rats immediately prior to TPTX and 5 hr
alter PTE or diluent injection for determining the
concentrations of calcium.
Administration of 1,25(OH)2D3 and 24,25-
(OH)2D3: Effect on the calcemic response to
PTE in acute uremia. Two experiments were car-
ried out. In both experiments, 20 rats were fed a
low-calcium diet for 4 days prior to study. In the
first experiment, 24 hr prior to the study, half the
rats were were injected i.v. with 325 pmoles of
24,25(OH)2D3. Then, on the day of the study, blood
samples were taken for determination of calcium
concentrations, 130 pmoles of 1 ,25(OH)2D3 were in-
jected, and TPTX and UL were performed, after
which, 40 U of PTE per 100 g of body wt were in-
jected. At the same time, the other half were treated
in a similar manner but injected with ethanol rather
than the vitamin D metabolite. The second experi-
ment was identical in all respects to the first, except
that Lilly diluent was used instead of PTE.
Chronicuremia
Calcemic response to PTE in chronic renal fail-
ure and the effect of 1,25(OH)2D3 administration.
Rats with chronic renal failure lasting 28 days were
used in this experiment. Renal failure was induced,
as described previously, in one operation by remov-
ing the right kidney and segmentally inlarcting two
thirds of the left kidney [8]. Weight-matched (but
not age-matched) rats that did not undergo a sham
abdominal operation were used as controls. The
test protocol for the uremic and the control groups
was as follows: 16 hr prior to TPTX, half of each
group was injected with 91 pmoles of 1 ,25(OH)2D3
and half with the vehicle ethanol. On the day of
study, all rats underwent TPTX; then half of each of
the I ,25(OH)2D3-treated and ethanol-' 'treated"
groups was given PTE, 40 U/100 g, and half of each
was given diluent. Five hours later, blood samples
were taken from all rats. There were five to seven
rats in each final experimental subgroup.
Biochemical methods were similar to those de-
scribed previously: plasma calcium concentrations
were determined by atomic absorption spectrome-
try, and phosphorus and creatinine concentrations
were determined by standard autoanalyzer II tech-
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nique [8, 9]. When vitamin D metabolites were mea-
sured, an aliquot of serum from each animal was
taken for measuring the calcium concentration;
then, the remainder of the serum from each experi-
mental group was pooled into 5-mi lots and kept fro-
zen at — 18° until the time of the assay. The assay
methods for the 1 ,25(OH)2D3 [10], the 24,25(OH)2D3
[11], and the 25-OH-D3 [12] have been described
previously.
For statistical assessment, Student's t test or,
where appropriate, analysis of variance was used.
All results are expressed as the mean SEM. In sev-
eral of the studies, the effect of PTE administration
on the plasma calcium concentration was deter-
mined by first calculating the mean plasma calcium
concentration 5 hr alter TPTX was performed in
the diluent-treated animals. This mean diluent value
was then subtracted from the plasma calcium con-
centration of each PTE-treated animal to give the
"net delta calcium" for that particular animal. The
mean of the "net delta calcium's" was then used for
the statistical calculation. In the other studies (e.g.,
"Vitamin D depletion and repletion with one micro-
gram of vitamin D2: Effect on calcemic response to
PTE in acute uremia"), the effect of PTE or TPTX
alone (diluent) was determined by subtracting the
calcium value immediately prior to TPTX from the
final calcium value 5 hr later to give a t5 — t0 cal-
cium value. This calculation was carried out be-
cause the group (e.g., that given the vitamin D re-
pletion) might be expected to have a different base-
line (t = 0) calcium value from the other group that
was still vitamin-D-deficient. In the chronic renal
failure study, baseline calcium concentration was
not measured. In any of the other studies where this
figure is not shown in the results, it was not neces-
sary, as there were no differences in the groups at
the t = 0 time.
Results
Five hours after NPX and UL, the mean plasma
creatinine concentrations were 1.2 0.03 mgIIOO
ml (N = 20) and 1.1 0.02 mgIlOO ml (N = 14),
respectively, compared with 0.4 0.01 mg/100 (N
= 20) in sham-operated controls.
Acute uremia
Time course of response to parathyroid extract
(PTE). The results of this study are shown in Figure
1. The NPX animals showed a delayed calcemic re-
sponse and never reached values as high as those of
sham-operated controls. All subsequent studies
were carried out at S hr, as the difference between
sham and NPX rats was well-marked at this time.
The two diluent-treated groups that were studied
at the same time (to enable the net change in cal-
cium concentration to be calculated) showed a
decrease in plasma calcium concentration over the
24-hr period of 0.3 0.8 mg/100 ml in the sham
group and 1.1 0.2 mg/100 ml in the NPX group.
Although the plasma calcium concentration in the
sham-operated animals showed little change over
the 24-hr period, there was an initial increase in
plasma calcium concentration to 1.2 0.3 mgIlOO
ml at 5 hr in the NPX group. The final plasma
calcium concentrations at 24 hr were 5.7 0.2 mgI
100 ml in the sham-diluent group and 6.2 0.1 mg/
100 ml in the NPX-diluent group.
PTE dose response in acute uremia. The dose re-
sponse curve is shown in Figure 2. There were sig-
nificant differences in plasma calcium concentra-
tions 5 hr following PTE challenge for all doses
used: P < 0.005 for the 10 UI100 g dose and P <
0.001 for the two higher doses. The difference in-
creased as the dose of PTE increased, and on this
basis, 40 U of PTE per 100 g of body wt was selected
as the dose for future studies. The final plasma cal-
cium values for the diluent-injected UL animals and
sham-operated animals that were studied at the
same time were 9.5 0.3 mgIlOO ml and 8.5 0.2
mgIlOO ml, respectively (seven rats in each group).
Ureteral ligation (UL) versus bilateral nephrecto-
my (NPX). The mean final plasma calcium and the
net change in calcium values are shown in Table 1.
The net change in calcium concentration of the
NPX group was not significantly different from that
+4
C
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Fig. 1. Time response curve of net change in plasma calcium
concentration after parathyroid extract (PTE), 40 UII00 g. Each
point is the mean SEM, corrected for diluent concentration
change. Thyroparathyroidectomized and bilaterally nephrecto-
mized (TPTX-NPX) animals are nephrectomized then injected
with PTE at time 0. These animals were TPTX 7 to 8 days prior
to day of use (five animals per group).
Time, hr
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Fig. 2. Dose response curve. Animals underwent thyropara-
thyroidectomy immediately prior to a bilateral ureter ligation
(UL) or a sham abdominal operation (referred to as "acute
TPTX"). They were then injected with parathyroid extract
(PTE). Values (mean SEM) are corrected for changes in diluent
concentrations.
of the UL group. Both these values were signifi-
cantly less (P <0.001) than that of the sham-oper-
ated animals. This study also demonstrates the
marked calcemic effect of NPX alone: mean plasma
calcium concentration of the TPTX-NPX-diluent
group was 13.0 0.3 mg/100 ml compared with 7.6
0.1 mg/100 ml in the TPTX-sham-diluent group.
This response to NPX has been studied previously
and has been shown to be due to a rise in plasma
citrate concentration [13, 14]. Probably for the same
reason, smaller rises in calcium were also noted in
the TPTX-UL-diluent rats and in the chronic
TPTX-NPX-diluent rats (Table 2).
Effect of dietary phosphorus on PTE response.
Although the starting and finishing calcium and
phosphate concentrations were widely different in
the two diet groups (Table 2), the NPX animals on
either diet showed a decreased calcemic response
to PTE. When the mean net change in values for
phosphorus are examined, it can be seen, however,
that this net change is greater following NPX than it
is following sham operation in both the diet groups.
The data from this experiment, therefore, does not
completely exclude an effect of phosphorus causing
some inhibition of the calcemic response to PTE in
the NPX groups.
Table 1. Comparison of calcemic effect of parathyroid extract
(PTE) in uremia produced by bilateral nephrectomy (NPX) or
bilateral ureteral ligation (UL)
Group
Plasma calcium
mg/IOO ml
Net A calcium
mg/100 ml
TPTX-sham + diluent 7.6 0.1
TPTX-sham + PTE 13.6 0.3 6.0 03b
TPTX-NPX + diluent 13.0 0.3
TPTX-NPX+PTE 15.1±0.1 2.l±0.2c
TPTX-UL + diluent 10.9 0.2
TPTX-UL + PTE 13.7 0.4 2.8 0.4
a All animals underwent thyroparathyroidectomy (TPTX) im-
mediately prior to abdominal operation. Blood samples were
taken 5 hr after P1'E injection (40 U/100 g) or diluent injection.
There were 8 to 10 rats in each group. Values are the mean
SEM. Delta (A) denotes change in concentration.
bP value between net change in calcium concentration in
TPTX-sham and TPTX-UL rats <0.001.
P value between net change in calcium concentration in
TPTX-NPX and TPTX-UL rats was not significant.
Relationship of serum vitamin D metabolite con-
centrations to PTE response. The principle aim of
this study was to determine whether the para-
thyroid resistance was associated with low concen-
trations of circulating vitamin D metabolites, The
difference in final calcium concentration between
PTE and diluent-treated animals following sham op-
eration was significantly greater than was the dif-
ference between PTE and diluent treatment fol-
lowing UL (F test, 13.9; P < 0.005; Table 3).
Table 3 also shows concentrations of 25-OH-D3,
I ,25(OH)2D3, and 24,25(OH)2D3 in the pooled sera
samples from each group (sera samples from all
eight rats per group contributed equally to the
pool). Because these are determinations on a single
specimen, we cannot comment on minor dif-
ferences; it is apparent, however, that there are
considerable amounts of each of the metabolites in
the circulation of the UL animals after 5 hr of
renal failure. All three metabolites appear slightly
higher in the animals given PTE whether their ure-
ters were ligated or not.
Effect of pretreatment with a pharmacologic dose
of 25-OH-D3, The results of this study are shown in
Table 4, The 25-OH-D3 treatment did not enhance
the calcemic response to PTE after 5 hr of ure-
mia. Interpretation of the difference in the con-
centrations of the circulating vitamin D metabolites
in pooled sera from the two groups must again be
limited for the reason mentioned above. Never-
theless, the 25-OH-D3 concentrations in the treated
group were obviously increased, as expected; in ad-
dition, the 24,25(OH)2D3 concentrations were prob-
ably increased compared with the nontreated
group. Failure of the 25-OH-D3 to elevate the base-
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Table 2. Plasma calcium and phosphorus concentrations in chronic TPTX rats before (t0) and 5 hr after (t5) injection of PTE (40 U/100 g)
or diluenta
TPTX-sham TPTX-NPX
Diluent PTE Diluent PTE
Dietb t t5 t0 t5 Net t t5 i t0 t5 Net i
0.2% Phosphate diet
Calcium,mgIIOOmi 11.6 9.1 —2.5 11.1 12.5 1.4 +4.0 13.0 15.3 +2.3 11.9 16.7 +4.8 +2.5c
Phosphate,mgIIOOml 8.8 8.7 —0.1 9.1 9.0 —0.1 —0.1 8.0 10.5 +2.3 10.1 14.3 +4.2 1.9
0.7% Phosphate diet
Calcium,mg/IOOmi 7.9 7.1 —0.8 8.4 12.0 3.6 +4.4 8.2 9.2 1.0 8.8 12.0 +3.2 +2.1c
Phosphate,mg/IOOml 15.4 14.6 —0.8 15.6 9.7 —5.9 —5.1 16.2 20.3 +3.8 16.0 19.5 3.2 —0.5
°There were 8 to 9 rats in each group. Values are the mean 5EM. Abbreviations are defined in Table I.
Phosphate content of diet for 72 hr before test.
cp values between net calcium in TPTX-sham and TPTX-NPX groups were <0.01 for 0.2% phosphate diet and <0.001 for 0.7%
phosphate diet.
line serum calcium concentrations was probably
due to the fact that the animals had been on a low-
calcium diet for 4 days.
Vitamin D depletion and repletion: Effect on the
calcemic response to PTE in acute uremia. The vi-
tamin-D-repleted group in this study showed a small
but significant increase in calcium concentration
following repletion. Mean plasma calcium concen-
trations rose from 9.2 0.1 mgIlOO ml immediately
before calciferol administration to 10.0 0.1 mgI
100 ml 48 hr later (P <0.001, 32 animals), indicating
some degree of vitamin D deficiency. In addition,
plasma 25-OH-D3 concentration in a group of six of
the vitamin-D-deficient animals was 5.3 1.1 ngl
ml, a value below the normal concentration found in
rats (mean, 22 2 nglml; N = 6). The plasma cal-
cium concentration results on the day of para-
thyroid challenge are shown in Table 5. In the vita-
min-D-defIcient group, PTE still produced a definite
calcemic response, mean plasma calcium concen-
tration rose 3.2 0.1 mg/lO0 ml, compared with a
fall of 2.0 0.2 in the diluent-treated controls. Fol-
lowing UL, these changes were less, +1.9 0.3
mg/100 ml in response to PTE and —1.1 mg!100 ml
in the diluent controls. The vitamin-D-treated ani-
mals, sham-operated, had a much greater response
to PTE: their mean calcium concentrations rose 5.9
0.3 mg/100 ml, compared with a fall of 1.1 0.3
mg!100 ml in the diluent controls. Following UL,
however, the PTE effect appeared to be reduced
(mean net change in calcium concentration, 0.4
0.1 mg/100 ml) compared with vitamin-D-deficient
UL animals (net change in calcium concentration,
3.0 0.3 mg/l00 ml). The overall difference in net
change in calcium concentration between the vita-
min-D-treated TPTX sham and the vitamin-D-
treated TPTX-UL rats was again significant (F test,
176.4; P <0.001).
1 ,25(OH)2D3 and 24 ,25(OH)2D3 administration:
Effect on calcemic response to PTE in acute ure-
Table 3. Serum calcium and circulating vitamin D metabolite concentrations in pooled sera 5 hr after PTE (40 U/lOO g) or diluent
injection in TP1'X rats that were either UL or sham-operated b
Group PTE
Mean serum
calcium
ngIIOO ml
Mean net
ca1ciumc
mg/lOOm!
25-OH-D3
nglml
24,25-OH-D3
ng/ml
I ,25-OH-D3
pg/mi
TPTX-sham no 4.9 0.2 7.4 10.4 116
TPTX-sham yes 12.3 0.8 7.4 0.8 10.3 18.1 188
TPTX-UL no 7.1 0.3 8.6 6.7 107
TPTX-UL yes 11.1 0.6 4.1 0.2 11.3 8.0 138
a Vitamin D2 or D, metabolites would not be differentiated in each assay.
bAll rats were on a calcium-free diet for 96 hr prior to the study. There were 8 animals in each group. Abbreviations are defined in
Table 1.
P between net calcium in TPTX-sham and TPTX-UL rats <0.005.
Vitamin D metabolites in renal failure 251
Table 4. Serum concentrations of circulating vitamin D metabolites and calcium 5 hr after injection of PTE (40 U/l00 g°)
Mean serum
calcium
mg/IOO rn!° Mean
calcium
mg/IOO ml
25-OH-D3
ng/mi
24,25(OH)2D3
ng/ml
I ,25(OH)2D3
pg/miGroup t0 t5
25-OH-D 9.6 0.2 10.5 0.5 0.9 0.4 180 35.3 70
Vehicle 10.1 0.1 10.8 0.3 0.7 0.3 9.7 12.5 121
° Blood samples were taken for the determination of calcium concentration from all rats which were then given TPTX and UL immedi-
ately prior to (t0) the injection of PTE. The 25-OH-D3 group was given 150 g of 25-OH-D3 48 hr prior to study. Both groups had been
fed a low-calcium diet for 4 days prior to the day of the experiment. There were eight rats in each group.
Abbreviations are defined in Table 1.
Difference in the mean serum calcium concentration at t0 and t5 between 25-OHD-D3 and vehicle groups was not significant.
mia. The administration of the 24,25(OH)2D3 was
done 24 hr prior to the study to allow time for meta-
bolic conversion to a more polar metabolite which
could possibly be more active [15, 161. This resulted
in a slightly but significantly higher calcium concen-
tration when the two 24,25(OH)2D3 groups were
compared with the two ethanol groups (t = 0 cal-
cium, 10.1 0.1 mgIlOO ml, respec-
tively; P < 0.02). As shown in Table 6, the net
change in calcium concentration is not significantly
different whether the animals were injected with ei-
ther ethanol or the vitamin D metabolites.
Chronic uremia
Calcemic response to PTE in chronic renal fail-
ure and the effect of 1 ,25(OH)2D3 administration.
The plasma creatinine concentrations of the kidney-
intact rats (0.3 0.01 mg/100 ml) was significantly
less than that of the chronic renal failure rats (1.2
0.1 mgIlOO ml; P < 0.001). As can be seen in Table
7, the response to PTE in kidney-intact animals was
much the same whether or not they received
1 ,25(OH)2D3. The animals with chronic renal fail-
ure, ethanol-injected, had a marked decrease in re-
sponse to PTE (mean net change in calcium concen-
tration, 0.9 1.0 mgIlOO ml) compared with kidney-
intact controls (6.5 0.4 mgIlOO ml; P < 0.001).
Prior treatment with 1 ,25(OH)2D3 resulted in a
greater calcemic response (4.1 0.8 mg/l00 ml)
but still significantly less (P < 0.01) than the
I ,25(OH)2D3-treated kidney-intact rats, (7.4 0.4
mg/100 ml).
Discussion
In the studies described, several different animal
models were used to examine parathyroid resis-
tance in acute renal failure. Thus, a wide range of
baseline and final plasma calcium concentrations
were obtained (Tables 1 and 2). Parathyroid hor-
mone resistance was demonstrated in all of these
models, indicating that the baseline or control
plasma calcium concentration is not an important
factor.
Previous studies have demonstrated that resis-
tance to parathyroid hormone develops as early as
24 hr after the induction of renal failure [61. Our re-
Table 5. Plasma calcium concentration before (t0) and 5 hr after (t5) PTE (40 U/l00 g) or an equivalent volume of diluent in rats after 5
weeks on a vitamin-D-deficient diet°
P1asma caIcium in TPTX-
mg/tOO ml
sham Plasma calcium in TPTX
mg/tOO ml
-UL
Diluent PTE Diluent PTE
Treatment t0 t5 t0 t5 Net i t0 t5 to t5 Net
VitaminDdeficientb 8.9 6.9 —2.0 9.0 12.2 3.2 5.2 8.9 7.8 —1.1 8.9 10.9 1.9 30d
VitaniinDtreatedc 10.0 8.9 —1.1 10.3 16.2 5.9 7.0 9.8 10.4 0.6 10.1 11.2 1.1 0.4°
TPTX and either UL or sham abdominal operation were carried out immediately before injection of hormone or diluent. There were
seven to eight animals per group. Abbreviations are defined in Table I.
° These rats were on a vitamin-D-deficient diet for 5 weeks.
Treatment was similar to the vitamin-D-deficient group except tg of vitamin D2 in oil was given by gavage 48 hr before the study.
Difference between net A calcium concentration in TP1'X and TPTX-UL groups was significant, F, 21.2; P < 0.001.
Difference between net A calcium concentration in TPTX and TPTX-UL groups was significant, F. 176.4; P < 0.001.
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Table 6. Plasma calcium concentration before (t0) and 5 hr after (t5) PIE (40 U/100 g) or diluent in rats pretreated with 325 pmoles of
24,25(OH)2D3 at 24 hr before t0 and 130 pmoles of I ,25(OH)2D3 at to, or equivalent volumes of ethanola
Treatment
Plasma calcium after
mg/i 00 ml
diluent Plasma calcium after PTE
mg/i00 ml
to t5 t0 t5 net &
1,25(OH)2D3 + 24,24(OH)2D3 9.9 7.8 —2.1 10.3 11.8 1,5 3.6
Ethanol 9.6 7.1 —2.5 10.0 10.9 1.1 3.7
a All rats were TPTX-UL at to and were given a low-calcium diet for 4 days prior to the day of study. Abbreviations are defined in
Table 1.
bP value between net calcium concentration in rats given 1 ,25(OH)2D3 + 24,25(OH)2D3 and ethanol was not significant.
suits (Fig. 1) show that in this rat model there is a
significant difference in the response of the plasma
calcium concentration to parathyroid extract injec-
tion between sham and renal failure animals after as
little as 3 hr. This and the fact that we failed to
find a difference in calcemic response between
ureter-ligated and bilaterally nephrectomized ani-
mals suggested that the resistance was not due to an
abnormality in the renal metabolism of vitamin D.
First, it would be expected that metabolic function
of the UL kidney would continue in a more or less
normal fashion for at least 5 hr. Second, it has
been shown that 1 ,25(OH)2D3 has a relatively long
duration of action [17]. Our subsequent experi-
ments substantiated this impression.
The demonstration of similar plasma concentra-
tions of both 1 ,25(OH)2D3 and 24,25(OH)2D3 in ren-
al failure and controls (Table 3) indicates that PTE
resistance in renal failure is not due to a fall in the
circulating concentrations of these two metabolites.
In addition, the higher levels of 25-OH-D3 and prob-
ably 24,25(OH)2D3 achieved by prior administration
of 25-OH-D3, 48 hr before induction of renal failure
(Table 4), did not change the calcemic response
when compared to the groups which did not receive
the 25-OH-D3. The use of a calcium-free diet in this
experiment would also be expected to encourage
the formation of the trihydroxyvitamin D metabo-
lite, 1,24,25(OH)2D3 [15, 16], which was not mea-
sured. This may or may not be important, as a re-
cent study has shown that all other naturally occur-
ring vitamin D metabolites are less active than
1,25(OH)2D3, at least in terms of bone resorption
[18].
If abnormal vitamin D metabolism was the major
factor in parathyroid hormone resistance, vitamin D
deficiency would be expected to reduce the calcem-
ic response to PTE in kidney-intact animals to the
level seen in renal failure. This was not the case (see
Table 5). It has been previously demonstrated that
parathyroid hormone has a reduced calcemic action
when vitamin D deficiency [19, 20] is present; we
have now demonstrated that uremia depresses this
action even further. Rats chosen for this study were
not severely deficient in vitamin D, thus, insuring
that they would show some response to PTE, and,
therefore, allowing any inhibitory effect of renal
failure to be observed. It has been demonstrated
Table 7. Plasma calcium concentration 5 hr after PTE (40 U/lOOg) or diluent in rats with intact kidneys or chronic renal failure of 28 day's
durationa
Treatment
Plasma calcium in T
mg/I00 ml
PTX Plasma calcium in TPT
mg/100 ml
X-CRF
Diluent PTH Nets Diluent PTH Nets
Ethanol' 8.2 14.7 +6.5 9.4 10.3 +0.9 <0.001
Ethanol + 1,25(OH)2D3d 8.5 15.9 +7.4 9.4 13.6 +4.1 <0.01
a All rats were TPTX immediately prior to PTE injection or diluent. There were 5 to 7 rats in each group. Abbreviations are defined in
Table 1.
b P value between net i in calcium concentration of TPTX and net in calcium concentration of CRF-TPTX rats.
0.1 ml of ethanol was administered i.v. 16 hr before test.
0.1 ml of ethanol containing 91 pmoles of l,25(OH)2D3 was administered iv. 16 hr before test.
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that severe vitamin D deficiency may completely in-
hibit the calcemic response to parathyroid hormone
[19]. That a degree of vitamin D depletion was pres-
ent in these rats was indicated by the moderately
depressed plasma calcium concentration, the rise in
plasma calcium concentration 2 days after the ad-
ministration of 1 sg of vitamin D2, and the height-
ened response to PTE in the sham-operated vita-
min-D-repleted group, compared with the sham-
operated vitamin-D-deficient group (Table 5).
More surprising was the calcemic response to
PTE after vitamin D repletion in the UL rats. This
appeared to be further depressed rather than re-
stored. The major factor responsible for this depres-
sion of calcemic response is the difference between
the sham-operated and UL rats given diluent. The
usual response in UL-diluent animals is a slight to
modest rise in calcium concentration, and, as dis-
cussed in the Results section, this is probably due to
changes in citrate metabolism. A fall, rather than a
rise, in calcium concentration in the UL-diluent vita-
min-D-deficient rats, is possibly related to the fact
that the plasma calcium concentration is being
maintained at the expense of higher levels of circu-
lating PTH. Following TPTX, this group would
therefore be expected to have a greater fall in cal-
cium concentration than, for example, would the vi-
tamin-D-treated group with the higher calcium con-
centration and probably lower PTH levels. The fall
in calcium concentration in UL-diluent animals on a
low-calcium diet (see Table 6) probably has a simi-
lar explanation.
Prior injection of both I ,25(OH)2D3 and
24,25(OH)2D3 in doses approximately physiologic
[15, 21] also failed to improve the calcemic response
(Table 6). It was of interest to note that the plasma
calcium concentration rose during the 24 hr be-
tween injection of 24,25(OH)2D3 and the t0 blood
sampling, which is in accord with previous studies
suggesting that this substance or a further metabo-
lite has a bone resorbing action [18]. Enhanced cal-
cium absorption could not have played a part, as the
animals were maintained on a calcium-free diet.
Partial correction of parathyroid resistance by
1 ,25(0H2D3 administration in the chronic renal fail-
ure model suggests that there are at least two com-
ponents to the parathyroid resistance after renal
failure has been present for a certain period, a vita-
min D factor and some other uremic factor. Canine
studies by Massry et al indicate that abnormality of
the vitamin D component also develops rapidly, in
as little as 24 hr [6] although in our model it has been
shown definitely not to be present at 5 hr.
The nature of this uremic factor has not been
demonstrated in these studies. Phosphate retention
has not been completely eliminated as the cause of
the parathyroid resistance, because of the different
changes in plasma phosphorus concentrations be-
tween sham and UL groups (Table 3). Osteoid accu-
mulation, which may have a role in the hypocalcem-
ic response in chronic renal failure [22], would not
be relevant in the 5-hr model. The modest elevation
of creatinine and urea concentrations are unlikely to
be responsible. Wills and Jenkins [23], who used an
in vitro system, examined the effect of various ure-
mic metabolites on PTE-mediated bone resorption.
They showed that high concentrations of urea and
creatinine were not inhibitory but that several other
metabolites known to accumulate in uremia were.
In addition, they demonstrated that whereas serum
from uremic patients immediately prior to hemo-
dialysis inhibited the PTE action, postdialysis
serum did not. It has been proposed that the action
of PTE in the short-term regulation of plasma cal-
cium concentration is not on bone resorption but on
calcium ion transport across the surface osteocyte
layer or blood bone barrier [24, 25]. We suggest that
parathyroid resistance in our acute renal failure
model is due to factors retained in uremia which
could affect the acute calcium translocation that is
induced within afew hours of PTE administration.
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